Tadalafil Side Effects: Clinical Evidence and Safety Profile

Quick answer

Tadalafil’s side-effect profile is dominated by headache (10 to 15 percent of trial participants), a tadalafil-specific back-pain pattern attributable to PDE11 cross-affinity (3 to 7 percent), flushing (3 to 5 percent), and dyspepsia (2 to 4 percent). Vision changes are rare with tadalafil compared to sildenafil. Hearing loss is a low-frequency class effect of PDE5 inhibitors. The single absolute contraindication is concurrent organic nitrate use (any route, any dose), which can produce potentially fatal hypotension. The long half-life means the nitrate washout window is 48 hours, twice as long as for sildenafil. Long-term safety has been characterized in a pool of 12 randomized trials with no clinically significant new signals through 1+ year of daily dosing.

Table of contents

1. Common side effects
2. Why tadalafil causes back pain (PDE11 mechanism)
3. Headache profile and tolerance
4. Cardiovascular safety
5. Vision and hearing
6. Priapism
7. Drug interactions
8. Contraindications
9. Frequently asked questions
10. References

---

Common side effects

The published incidence ranges for tadalafil’s most common adverse events (those reported in at least 1 percent of trial participants) are summarized below. The data source is the integrated long-term safety pool of 12 randomized double-blind placebo-controlled phase II and phase III trials of 5 mg once-daily tadalafil, evaluated against placebo in patients with LUTS/BPH or ED. According to PubMed, this pool includes patients aged 75 years and older as a sub-population, with no clinically significant differences in long-term tolerability between younger and older men (Oelke et al., 2017, PMID 27988986, DOI).

Adverse event	Approximate incidence	Pattern
Headache	10 to 15%	Frontal or bitemporal; peaks 1 to 2 h post-dose
Back pain or myalgia	3 to 7%	Dose-dependent; higher at 20 mg than 5 mg
Flushing	3 to 5%	Vasodilation-related; transient
Dyspepsia	2 to 4%	Smooth-muscle effect on lower esophageal sphincter
Nasal congestion	1 to 3%	Vasodilation-related
Limb pain	1 to 3%	Often groups with back pain in pooled reports
Visual disturbances	<1%	Rare with tadalafil; PDE6 cross-affinity is minimal

The first-week incidence is typically the peak. Headache and back pain attenuate with continued dosing in most users, though a minority continue to experience persistent symptoms that limit tolerability.

Why tadalafil causes back pain (PDE11 mechanism)

Back pain and myalgia are the most distinctive adverse events in tadalafil’s profile. They are reported at a higher rate with tadalafil than with sildenafil or vardenafil at equivalent doses. The pattern is typically dull, low-back, develops 12 to 24 hours after dosing, lasts approximately 12 to 48 hours, and is most pronounced in the first 1 to 2 weeks of dosing before attenuating.

The leading molecular hypothesis is PDE11 cross-affinity. PDE11 is a phosphodiesterase isoform expressed in skeletal muscle, prostate, testis, salivary gland, and pituitary tissue. According to PubMed-indexed selectivity profiling, tadalafil has measurable inhibitory affinity for PDE11A1, with selectivity for PDE5 over PDE11 that is significantly lower than the corresponding ratio for sildenafil and vardenafil (Wang et al., 2013, PMID 23937247, DOI).

PDE11 inhibition in skeletal muscle alters local cyclic nucleotide signalling. The downstream effects on muscle metabolism are not fully characterized, but the temporal pattern (12 to 48 hour onset, attenuation with chronic dosing) is consistent with a peripheral mechanism that downregulates with sustained exposure. According to PubMed, drug-design literature has explicitly attempted to identify PDE5 inhibitors with reduced PDE11 cross-affinity to mitigate the back pain signal; this is treated as a known limitation of the tadalafil-class molecular scaffold (Kayık et al., 2017, PMID 28150511, DOI).

The dose-response is monotonic. Reported incidence is approximately 3 percent at 10 mg, approximately 7 percent at 20 mg, and lower at the 5 mg daily dose. For researchers experiencing back pain at 20 mg on-demand, stepping down to 10 mg or switching to 5 mg daily is the published management approach.

Headache profile and tolerance

Headache is the most common tadalafil adverse event. The pattern is well-characterized:

• Onset: 1 to 2 hours after oral dose, coinciding with peak plasma concentration.
• Location: frontal or bitemporal; less commonly occipital.
• Severity: typically mild to moderate; rarely severe.
• Duration: 4 to 8 hours; resolves before 24 hours in most cases.
• Tolerance: most users develop tolerance within 1 to 2 weeks of continuous daily dosing. On-demand dosing does not produce the same tolerance because the dosing interval prevents adaptation.

Acetaminophen and NSAIDs are commonly effective for symptom management. The headache is presumed vasodilatory in mechanism (the same vasodilation that produces facial flushing) and does not represent a serious adverse event in the absence of other red flags. Severe or atypical headache, particularly with vision changes, warrants discontinuation and evaluation.

Cardiovascular safety

Tadalafil’s cardiovascular safety has been characterized across hemodynamic, exercise, and long-term outcome studies. The class effect is mild systemic vasodilation. According to PubMed, hemodynamic studies report decreases in systolic and diastolic arterial pressure averaging approximately 9 by 8 mmHg at rest, increasing to approximately 12 by 5 mmHg during the vasodilatory peak. Exercise studies in patients with stable coronary artery disease have identified no adverse-event potential for sildenafil, vardenafil, or tadalafil; one study reported sildenafil produced an anti-ischemic effect by increasing time to limiting angina (Jackson 2005, PMID 16387564, DOI).

The long-term cardiovascular safety pool is favorable. According to PubMed, the integrated analysis of 12 randomized trials of 5 mg once-daily tadalafil in LUTS/BPH and ED populations reported no signal of increased cardiovascular adverse events compared with placebo, including in the sub-population aged 75 years and older (Oelke et al., 2017, PMID 27988986, DOI).

The cardiovascular contraindication map:

• Absolute: organic nitrates (any route, any dose), riociguat, severe cardiovascular disease (recent myocardial infarction within 90 days, unstable angina, NYHA class III or IV heart failure, uncontrolled hypertension or hypotension, history of stroke within 6 months).
• Relative: stable angina on antianginal therapy other than nitrates, controlled hypertension on antihypertensive medication, mild to moderate hepatic or renal impairment.
• Standard care: blood pressure measurement at baseline, week 1, week 4, and week 12 of any new tadalafil protocol.

Vision and hearing

Vision. Tadalafil’s selectivity profile produces fewer vision-related adverse events than sildenafil. The PDE5/PDE6 selectivity ratio is significantly higher for tadalafil than for sildenafil, which means tadalafil produces less inhibition of the retinal phototransduction cascade. Sildenafil’s classic transient blue-tint vision and impaired blue-yellow discrimination are uncommon with tadalafil.

Non-arteritic anterior ischemic optic neuropathy (NAION) is a rare but serious class effect of PDE5 inhibitors. According to PubMed, a literature review published in the Canadian Journal of Urology in 2006 reported fewer than 50 cases of NAION associated with PDE5 inhibitor use to the FDA and 5 cases to Health Canada. Causal attribution remains difficult because NAION shares its primary risk factors (age over 50, dyslipidemia, diabetes, hypertension, smoking) with the cardiovascular comorbidities common in PDE5 inhibitor users. The recommended approach is informed-consent disclosure of the low risk and immediate cessation if vision changes occur (Bella et al., 2006, PMID 17076943).

Sudden vision loss, with or without pain, is a discontinuation indication. The patient should seek immediate ophthalmologic evaluation.

Hearing. Sudden sensorineural hearing loss (SNHL) is a low-frequency class effect of PDE5 inhibitors. According to PubMed, a 2018 retrospective population-based cohort study using the MarketScan Commercial Claims and Encounters Database evaluated 377,722 men who initiated a PDE5 inhibitor and 1,957,233 nonusers between 1998 and 2007. The incidence of sudden SNHL was 4.35 per 10,000 person-years for current users, 5.58 for recent users, and 2.38 for nonusers. The age- and propensity-adjusted hazard ratio for current use was 1.25 (95 percent CI 1.01 to 1.55), with a risk difference of 1.97 per 10,000 person-years. The increased risk is small in absolute terms but statistically significant (Liu et al., 2018, PMID 29512263, DOI).

The mechanism is not fully characterized. Sudden unilateral or bilateral hearing loss, with or without tinnitus or vertigo, is a discontinuation indication and warrants immediate otologic evaluation.

Priapism

Priapism (a prolonged erection lasting more than 4 hours) is a rare but serious adverse event reported across all PDE5 inhibitors. The molecular pathophysiology centers on dysregulated nitric oxide signalling in the cavernous tissue, with the cGMP-dependent vasodilation that PDE5 inhibition prolongs failing to terminate appropriately. According to PubMed, the populations at highest risk include patients with sickle cell disease (the most common population in priapism case series), multiple myeloma, leukemia, anatomical predisposition, and concurrent use of other vasoactive medications (Anele et al., 2015, PMID 25392014, DOI).

A priapism episode lasting more than 4 hours is a urological emergency. Untreated priapism can cause cavernosal smooth-muscle ischemia and permanent erectile dysfunction. The standard management approach is urgent cavernosal aspiration with phenylephrine irrigation; surgical intervention is reserved for refractory cases.

For research protocols, priapism risk warrants screening: known sickle cell disease, multiple myeloma, leukemia, or anatomical predisposition are relative contraindications to PDE5 inhibitor protocols, and informed consent should explicitly cover the priapism risk with instructions to seek emergency care if an erection lasts more than 4 hours.

Drug interactions

CYP3A4 substrates. Tadalafil is metabolized predominantly by hepatic CYP3A4. Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, certain macrolide antibiotics like clarithromycin) substantially elevate tadalafil plasma exposure. The published guidance is dose reduction: where the standard dose would be 10 or 20 mg, the appropriate dose with concurrent strong CYP3A4 inhibitor exposure is 2.5 to 5 mg. Strong CYP3A4 inducers (rifampicin, phenytoin, carbamazepine, St. John’s Wort) reduce tadalafil exposure and may render standard doses sub-therapeutic. Grapefruit juice is a moderate CYP3A4 inhibitor and produces a modest exposure increase, less clinically significant than the strong inhibitors above (Corbin and Francis 2002, PMID 12166544).

Alpha-blockers. Alpha-1 adrenergic receptor antagonists (tamsulosin, alfuzosin, doxazosin, terazosin) lower blood pressure through smooth-muscle relaxation in the vasculature, prostate, and bladder. Co-administration with tadalafil produces additive hypotension. With prostate-selective alpha-blockers (tamsulosin and alfuzosin), the interaction is generally well-tolerated at standard doses, and the combination is in fact a routine clinical pattern in BPH management. With non-selective alpha-blockers (doxazosin, terazosin), more caution is warranted; staggered dosing and starting at a lower tadalafil dose is the published approach.

Antihypertensives. Co-administration with antihypertensive medications produces small additional blood pressure decreases, generally within 5 mmHg systolic. The interaction is mild and does not contraindicate the combination at standard doses.

Alcohol. Moderate alcohol (up to approximately 3 standard drinks) does not meaningfully alter tadalafil pharmacokinetics. Heavy alcohol can produce additive vasodilation and orthostatic hypotension, a class effect shared across PDE5 inhibitors.

Contraindications

Absolute contraindication 1: organic nitrates. Co-administration of any PDE5 inhibitor with an organic nitrate (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) can produce profound, potentially life-threatening systemic hypotension. The mechanism is additive vasodilation: nitrates donate nitric oxide, which activates the same cGMP pathway that PDE5 inhibition prolongs. The two effects do not summate linearly. They potentiate. According to PubMed, the contraindication is absolute and applies regardless of the route of nitrate administration (oral, sublingual, transdermal, intravenous). The 17.5-hour half-life means the contraindication window extends 48 hours after the last tadalafil dose (Doumas et al., 2015, PMID 25392015, DOI).

The contraindication extends to recreational alkyl nitrites (so-called “poppers”), which are pharmacologically equivalent to organic nitrates for this interaction.

Absolute contraindication 2: riociguat. Riociguat is a soluble guanylate cyclase (sGC) stimulator approved for pulmonary hypertension. It activates the same cGMP pathway from upstream of PDE5. Co-administration with a PDE5 inhibitor produces additive vasodilation analogous to the nitrate interaction.

Absolute contraindication 3: severe cardiovascular disease. Recent myocardial infarction (within 90 days), unstable angina, NYHA class III or IV heart failure, uncontrolled hypertension or hypotension, history of stroke within 6 months, or hemodynamically significant left ventricular outflow obstruction.

Relative contraindications. Severe hepatic impairment (Child-Pugh class C), severe renal impairment (creatinine clearance less than 30 mL/min), known hypersensitivity to tadalafil or any inactive ingredient, concurrent strong CYP3A4 inhibitor or inducer (manage by dose adjustment), and anatomical or hematological priapism risk factors discussed above.

Frequently asked questions

What is the most common side effect?
Headache, reported by 10 to 15 percent of trial participants across all dose strengths. Typically frontal or bitemporal, peaks 1 to 2 hours post-dose, resolves within 6 hours. Usually self-limiting and tolerance often develops within the first 1 to 2 weeks.

Why does tadalafil cause back pain?
Tadalafil has measurable affinity for PDE11, a phosphodiesterase enzyme expressed in skeletal muscle. PDE11 inhibition is the proposed mechanism for the tadalafil-specific back pain and myalgia pattern (3 to 7 percent incidence) that distinguishes it from sildenafil and vardenafil.

Is the back pain dose-dependent?
Yes. Incidence is approximately 3 percent at 10 mg and 7 percent at 20 mg in pooled trial data. Daily 5 mg has lower incidence than 20 mg on-demand.

What are the absolute contraindications?
Concurrent use of organic nitrates (nitroglycerin, isosorbide dinitrate, isosorbide mononitrate) and concurrent use of riociguat. Both can produce profound, potentially fatal hypotension. Recreational nitrites (“poppers”) fall under the same restriction.

How long should one wait before nitrates after tadalafil?
Because tadalafil’s half-life is 17.5 hours, a 48-hour washout is recommended before any nitrate administration. This is significantly longer than the 24-hour washout sufficient for sildenafil.

Does tadalafil cause vision changes?
Vision-related adverse events are rare with tadalafil compared to sildenafil. Tadalafil has minimal PDE6 cross-affinity (PDE6 is enriched in retinal photoreceptors). Sildenafil’s blue-tint vision change is uncommon with tadalafil. Rare reports of NAION (non-arteritic anterior ischemic optic neuropathy) exist; sudden vision loss is a discontinuation indication.

Are there any hearing-related concerns?
Sudden sensorineural hearing loss has been reported as a class effect of PDE5 inhibitors at very low frequency. A 2018 population-based cohort study estimated a small but significant increased risk. The mechanism is unclear. Sudden hearing loss is a discontinuation indication.

What about priapism?
Priapism (erection lasting more than 4 hours) is a rare but serious adverse event of all PDE5 inhibitors. Anatomical predisposition (sickle cell disease, multiple myeloma, leukemia) increases risk. Priapism greater than 4 hours requires emergency evaluation.

References

References sourced via PubMed.

---

Research use only. Not medical advice. Tadalafil is Schedule F in Canada.

Related reading

• Tadalafil pillar guide
• Tadalafil dosage guide
• Tadalafil vs sildenafil comparison
• Tadalafil protocol